Product Development
Immunostimulatory Factors and Therapeutic Antibodies
Setting # 1
|
|
|
|
Product |
ImmuFact
IMP321 Monotherapy |
|
|
|
|
Therapeutic indications |
Metastatic Renal Cell
Carcinoma (MRCC) Chronic Hepatitis C |
|
|
|
|
Approach |
IMP321 alone (high dose
for systemic exposure) |
|
|
|
|
Mechanism of action |
T cell immune response
stimulation as a monotherapy |
|
|
|
|
Development Phase |
Phase I/IIa |
|
|
|
|
Status of development
phase |
MRCC: completed |
|
|
|
|
Preclinical results |
Proof of concept in animal
models No toxicity |
|
|
|
|
Clinical results |
|
|
|
|
Setting # 2
|
|
|
|
Product |
ImmuFact
IMP321 Chemo-Immunotherapy |
|
|
|
|
Therapeutic indications |
Metastatic breast cancer
(MBC) Advanced pancreatic cancer |
|
|
|
|
Approach |
Chemotherapy followed by
IMP321 alone (high dose for systemic exposure) |
|
|
|
|
Mechanism of action |
T cell immune response
stimulation with chemo-immunotherapy |
|
|
|
|
Development Phase |
Phase I/IIa |
|
|
|
|
Status of development
phase |
MBC: in progress ( Advanced pancreatic cancer
to start in Q4 2008 |
|
|
|
|
Preclinical results |
Proof of concept in animal
models No toxicity |
|
|
|
|
Clinical results |
|
|
|
|
Setting # 3
|
|
|
|
Product |
ImmuFact
IMP321 Adjuvant |
|
|
|
|
Therapeutic indications |
Post-surgery melanoma Metastatic melanoma Ovarian cancer |
|
|
|
|
Approach |
Low dose IMP321 mixed with
antigen |
|
|
|
|
Mechanism of action |
T cell immune response
stimulation as an adjuvant for therapeutic vaccines |
|
|
|
|
Development Phase |
Phase I/IIa |
|
|
|
|
Status of development
phase |
Post-surgery melanoma: in
progress Metastatic melanoma: in
progress |
|
|
|
|
Preclinical results |
Proof of concept in
animals models No toxicity |
|
|
|
|
Clinical results |
|
|
|
|
Setting # 4
|
|
|
|
Product |
ImmuTune
IMP701 Antagonist Antibody |
|
|
|
|
Therapeutic indications |
Cancer Chronic infectious
diseases |
|
|
|
|
Approach |
Monoclonal antibody |
|
|
|
|
Mechanism of action |
Blockade of immune
down-regulation |
|
|
|
|
Development Phase |
Preclinical |
|
|
|
|
Status of development
phase |
Optimisation |
|
|
|
Setting # 5
|
|
|
|
Product |
ImmuTune IMP731
Depleting Antibody |
|
|
|
|
Therapeutic indications |
Autoimmune diseases and
transplantation |
|
|
|
|
Approach |
Monoclonal antibody |
|
|
|
|
Mechanism of action |
Killing activated T cells |
|
|
|
|
Development Phase |
Preclinical |
|
|
|
|
Status of development
phase |
Moving into clinical
production |
|
|
|
